Alizé Pharma Report issue

For profit Phase 1
Founded: Ecully France (2015)
Status: Acquired by Millendo Therapeutics, Inc. (2017) → now Tempest Therapeutics (2021)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 1 Trials (1)

Livoletide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Overweight (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1